The Worldwide Market for IVD Tests, 19th Edition

Chapter 1: Executive Summary

About Kalorama Information

Overview

• Figure 1-1: Worldwide IVD Market Sales, 2020, 2025, and 2030 ($ billion)
• Figure 1-2: COVID-19 IVD Market, Share by Segment, 2025 (%) [Immunoassay Lab-Based, Molecular Dx Lab-Based, Point-of-Care]

Scope and Methodology

Size and Growth of the Market

• Table 1-1: Global In Vitro Diagnostic (IVD) Sales, by Product Segment, 2025-2030 ($ million) [Blood Bank Molecular; Blood Bank Screening; Drugs of Abuse; Blood Grouping/Typing; Circulating Tumor Cells; Clinical Chemistry; Coagulation; Histology/Cytology; Continuous Glucose; Diabetes HbA1c Immunoassays, Lab-Based;  Hematology;  HPV, Molecular; Immunoassays – Infectious Disease;  Immunoassays – Other; Mass Spectrometry; Microbiology (ID/AST); Molecular Microbiology; Nucleic Acid Assays; POC, OTC Diabetes; POC, OTC Other; POC, Professional; Other]

Market Highlights

Market Assumptions

• Table 1-2: IVD Market Assumptions 2025 Outlook

Competitive Picture in IVD

Finding What You Are Looking For in the 19th Edition

• Table 1-3: Finding What You Are Looking For in the 19th Edition

 

Chapter 2: Introduction

IVD Landscape

Scope

Edition-Specific Notes

• Shifting Areas of Concentration

Report Design

PAMA and CMS

Market Analysis of IVD Market Segments

• Table 2-1: Global In Vitro Diagnostic (IVD) Sales, by Product Segment, 2025-2030 ($ million) (%) [Blood Bank Molecular; Blood Bank Screening; Drugs of Abuse; Blood Grouping/Typing; Circulating Tumor Cells; Clinical Chemistry; Coagulation; Histology/Cytology; Continuous Glucose; COVID-19 Dx; Diabetes HbA1c Immunoassays, Lab-Based;  Hematology;  HPV, Molecular; Immunoassays – Infectious Disease;  Immunoassays – Other; Mass Spectrometry; Microbiology (ID/AST); Molecular Microbiology; POC, OTC Diabetes; POC, OTC Other; POC, Professional; Other]
• Table 2-2: Additional Global In Vitro Diagnostic (IVD) Markets of Interest (Not in Totals), Sales by Product Segment, 2025-2030 ($ million) (%) [Clinical Sequencing; Drugs of Abuse, Criminal; Drugs of Abuse, Employment (non IVD); DTC Genetic Testing; Flow Cytometry; Prenatal Test Services]

Top Suppliers and Niche Players

Introduction

Overview of the Top Tier Companies

• Table 2-3: Clinical Diagnostic Revenues of Selected Top 20 IVD Companies, 2024 and 2025 ($ million)

Abbott Diagnostics

Roche Diagnostics

Danaher Corporation

Cepheid

Radiometer

Beckman Coulter

Thermo Fisher Scientific

Dexcom

Siemens Healthineers

bioMérieux

Illumina

Exact Sciences

Sysmex Corporation

Becton Dickinson & Co

QuidelOrtho Corporation

Werfen

Natera

Mindray

Hologic

Agilent

Bio-Rad Laboratories

QIAGEN N.V.

Revvity

Overview of Selected Second-Tier Companies

• Table 2-4: Revenues of Selected Top 20 Niche IVD Players, 2024 and estimated 2025 ($ million)
• Figure 2-1: Top Tier Market Distribution, 2024 and estimated 2025 (%)

Diasorin Group

Bruker/CALID Group

Guardant Health

Myriad Genetics

Grifols S.A.

Diagnostica Stago

BGI Genomics

Sekisui Diagnostics

ARKAY

GeneDx

Fujirebio

Fulgent Genetics

Seegene

Horiba

Randox

Eiken Chemical Co

Nihon Kohden

Meridian

Menarini Diagnostics

Haemonetics

IVD Companies Mergers & Acquisitions

• Table 2-5: Selected IVD Mergers and Acquisitions, 2023-2026 (first half)

Collaboration, Partnership, Alliance Agreements

Test Services

• Figure 2-2: Clinical Laboratory Test Service Market Forecasted Growth, by Segment, 2024-2029 (%)
• Table 2-6: Global Lab Market Segmentation, 2024 ($ billion) [Hospital and Acute Care Labs, Independent Labs, Physician Office Labs]
• Table 2-7: Total Revenues for Leading U.S.-based Reference Labs, 2023-2025 ($ million)

Historical IVD Market vs Today

In the Beginning to Now

• Figure 2-3: Share of Global IVD Market, by Segment, 2000 and 2025 Compared (%) [Blood Banking (imm & typing); Clinical Chemistry; Coagulation; Hematology; Immunoassays; Microbiology [ID/AST]; Molecular; POC – Other; Histology/Cytology; POC Diabetes; Others]

Future

Next-Generation Sequencing

Cancer Testing (Liquid Biopsy)

Companion Diagnostics

Chapter 3: The Global Picture for In Vitro Diagnostic Markets

Scope

Overview

Simultaneous Threats: Chronic and Acute

Expected World IVD Market Developments

Global Population and Aging

• Figure 3-1: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
• Figure 3-2: Global Population Distribution, 2025
• Table 3-1: Elderly Support Ratio in Various Countries, 2010 and 2050 [Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World]

Workforce Reduction

WHO Essential IVD List

• Table 3-2: WHO Model List of Essential In Vitro Diagnostics (EDL)

Increase in Chronic Diseases

• Figure 3-3: Leading Causes of Death Globally, 2021* (number of deaths in millions)

COVID-19

• Table 3-3: Selected Molecular EUA Tests for COVID-19, 2024-July 2025
• Table 3-4: Selected Antigen Immunoassay Tests for SARS-CoV-2, 2024-2025

Emerging and Emerged Markets

• Table 3-5: Developed/Developing Economies, UN Classification* Table, 2025
• Figure 3-4: Developed vs. Developing IVD Market Shares, 2025 and Projected 2030 (%)
• Table 3-6: Countries To Watch for IVD Opportunities, by Total Population and Percent Urban, 2025 [Australia; Brazil; China; France; Germany; Hungary; India; Mexico; Netherlands; Poland; Romania; Saudi Arabia; South Africa; South Korea; Sweden; Switzerland, Turkey; United Kingdom; United States]

Size and Forecast for the Global IVD Market

• Table 3-7: Global In Vitro Diagnostic Market, Major Country/Region Markets, 2025 and 2030 ($ million) [Australia; Brazil; Canada; China; Eastern Europe; EU 15/W. Europe; India; Japan; Mexico; Peru; Russia; Saudi Arabia; South Africa; South Korea; Turkey; UAE; United States; Vietnam; Rest of World]
• Table 3-8: Global In Vitro Diagnostic Market, Regional Markets, 2025 and 2030 ($ million) [Africa, Asia Pacific, Europe, Latin America, Middle East, North America]
• Table 3-9: Global In Vitro Diagnostic Market, YOY Growth, by Segment, 2024-2025 (%) [Blood Bank Molecular; Blood Bank Screening – Immunoassays; Blood Grouping/Typing; Clinical Chemistry; Coagulation (PT/INR, Molecular); D-dimer; Diabetes HbA1c, Lab; Drugs of Abuse; Hematology – Core Lab; Histology/Cytology; Immunoassays – Infectious Disease; Immunoassays – Other Immunos; Mass Spectrometry (Micro/Non-Micro); Microbiology (ID/AST); Microbiology (Molecular); NAAT – Oncology; NAAT – Genetic/Inherited; POC, OTC Glucose OTC; POC Continuous Glucose; POC, OTC Other; POC, Professional/Hospital]
• Table 3-10: Global In Vitro Diagnostic Market, Regional Markets, 2024-2025 YOY Change (%) [Africa, Asia Pacific, Europe, Latin America, Middle East, North America]

The IVD Market in the United States

• Table 3-11: United States IVD Market Share, by Segment, 2025 (%) [Blood Grouping; Clinical Chemistry; Coagulation; Hematology; Histology; Immunoassay Infectious Disease; Immunoassay Other; Microbiology ID/AST; Microbiology Molecular; Nucleic Acid Assays; POC Diabetes; POC Other; Others]

PAMA and Reimbursement Changes

Impact of CARES Act on PAMA

• Table 3-12: Proposed Clinical Diagnostic Laboratory Test (CDLT) Rates, 2020-2027

Saving Access to Laboratory Service Act (SALSA)

LDT Update

Bundled Insurance Payments for ESRD Patients

• Table 3-13: Laboratory Tests Subject to ESRD Consolidated Billing

Advanced Laboratory Tests (ADLT)

• Table 3-14: List of Approved ADLTs, March 2026

Precision Medicine and NGS

IVD Market in Europe

• Figure 3-5: International Monetary Fund Inflation Map, Global 2024
• Table 3-15: Western European IVD Market, by Country, 2025 ($ million, estimated) [Austria; Belgium; Denmark; Finland; France; Germany; Greece; Ireland; Italy; Luxembourg; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; UK]

EU Regulation

• Table 3-16: IVD Market Per Capita, Europe, 2025 Estimates [Bulgaria; Croatia; Czech Republic; France; Germany; Greece; Hungary; Italy; Lithuania; Netherlands; Poland; Romania; Russia; Serbia; Slovakia; Slovenia; Spain; Sweden; Switzerland; Ukraine; UK]

Precision Medicine in Europe

Brexit

Japan

• Table 3-17: Japan IVD Market, Share by Segment, 2025 (%) [Clinical Chemistry; Coagulation; Hematology; Histology; Immunoassay Infectious Disease; Immunoassay Other; Microbiology ID/AST; Microbiology Molecular; POC Diabetes; POC Other; Others]

Eastern Europe: Growth Region

• Table 3-18: Eastern European IVD Market, by Country, 2025 ($ million) [Bulgaria; Croatia; Czech Republic; Hungary; Poland; Romania; Slovakia; Slovenia; Ukraine; Other]
• Figure 3-6: Eastern Europe IVD Market, by Country, 2025 ($ million) [Bulgaria; Croatia; Czech Republic; Hungary; Poland; Romania; Slovakia; Slovenia; Ukraine; Other]

China: Current IVD Market

• Table 3-19: China IVD Market, Share by Segment, 2025 (%) [Blood Bank Screening; Clinical Chemistry; Coagulation; Hematology; Histology; Immunoassay Infectious Disease; Immunoassay Other; Microbiology ID/AST; Microbiology Molecular; POC Diabetes; POC Other; Others]
• Table 3-20: Total Midyear Population, by Broad Age Group: China, 2010-2050 (million persons)

Clinical Laboratory Market in China

Volume-Based Procurement in China

India: Population and Opportunity

• Table 3-21: India IVD Market, Share by Segment, 2025 (%) [Clinical Chemistry, Hematology, Coagulation; Histology/Cytology; Immunoassays; Microbiology/Virology; POC Glucose; POC Other; Others]

Clinical Laboratory Market in India

IVD Regulation

India’s Mukt Bharat Campaign

Rest of Asia

• Table 3-22: Asia Pacific Region IVD Market, by Country, 2025 ($ million) [Australia; China; India; Indonesia; Japan; Malaysia; Philippines; Singapore; South Korea; Thailand; Vietnam]

Brazil

• Table 3-23: Brazil IVD Market, by Broad Segment, 2025 (%) [Core Lab; Histology; Immunoassays; Microbiology/Virology; Point-of-Care – glucose; Point-of-Care – other]

Disease Trends

Clinical Laboratory Market in Brazil

IVD Regulation

Mexico

• Table 3-24: Mexico IVD Market, by Broad Segment, 2025 (%) [Clinical Chemistry, Hematology, Coagulation; Histology; Immunoassays; Microbiology; Point-of-Care; Others]

The Russian Federation

Canada

Emerging Markets

Saudi Arabia IVD Market

South Africa IVD Market

South Korea IVD Market

Turkey IVD Market

United Arab Emirates (UAE) IVD Market

Other Markets to Watch

Chile

Colombia

Indonesia

Malaysia

Peru

Philippines

Poland

Romania

Thailand

Vietnam

IVD Market Opportunity by Country

• Table 3-25: IVD Market Opportunity, by Country (2025 Market Rank, Country CAGR 2025-2030) (%)

Chapter 4: Company and Industry Trends

Scope

Edition-Specific Notes

Advanced Medicine Without Borders

• Table 4-1: Key Emerging IVD Markets, 2020-2025 ($ million)

China Market Update

Direct to Consumer Genetic Test Services

Genetic Testing in Disease

Genomic Testing

Gene Editing

• Table 4-2: Selected Gene Editing / CRISPR Innovations

CRISPR as a Diagnostic Tool

CRISPR and the Food Industry

Microbiome

• Table 4-3: Selected Microbiome Test Innovations

Next-Generation Sequencing

• Table 4-4: Selected Clinical NGS Platforms on the Market

Liquid Biopsy

Quality Assurance

Product News

Market Cleared Products

Liquid Biopsy in Microbiology

Liquid Biopsy Companies in 2022-2025

The Future for Liquid Biopsy

Information Technology Advances and Artificial Intelligence

AI in Clinical Practice

• Table 4-5: Selected AI Market Cleared Tests

AI Physician Usage

The Regulatory Pathway

Product Initiatives

• Table 4-6: Selected AI Product Initiatives in Development and Collaborations

AI in Liquid Biopsy

Role of AI in Liquid Biopsy Interpretation

Industry Leaders and Initiatives

New Liquid Biopsy / AI Products in Development or Recently Launched

• Table 4-7: Selected AI/Liquid Biopsy Initiatives

Future Trends

Exosome Sequencing

Biotin Interference in Immunoassay Detection Errors

• Table 4-8: Biotin-free Offerings Currently on the Market
• Table 4-9: Biotin Interference with Troponin Lab Tests – Assays Subject to Biotin Interference

Clinical Applications and Liquid Biopsy

Traumatic Brain Injury and IVD

Personalized Medicine

Companion Diagnostics

• Table 4-10: Selected FDA Approved Companion Diagnostics 2025

Telehealth

Blockchain

Substance Abuse

Biomarkers and Substance Abuse

Clinical Laboratory Testing for Drugs of Abuse

• Table 4-11: Global Drug Abuse Statistics

Urine

Blood

Oral

Hair

Saliva Testing

Breath Test Advances

• Table 4-12: Selected Disease Markers in Exhaled Breath

Micro-Hospital Opportunities

Climate Change and Infectious Disease

Kickback Schemes

Early Sepsis Detection

Medical Diagnostics and 3D Printing

Staffing Shortages

Targeted Testing

 

Chapter 5: Point-of-Care (POC) Tests

Scope

Overview and Trends

POC Industry Drivers

Patient-focused drivers

Medical/Healthcare-related drivers

Technology drivers

Economic drivers

Other drivers

POC Industry Challenges

Regulatory Challenges

Professional POC

• Table 5-1: Worldwide Professional POC Test Sales, by Category, 2025 -2030 ($ million) [Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urinalysis; Others]
• Table 5-2: Selected Professional POC Test Innovations (excluding COVID-19 testing)

OTC Self Testing

• Table 5-3: Worldwide POC Self-Test Sales, by Category, 2025-2030($ million) [Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self;  pylori; HIV; Other Infectious Disease (inc. COVID-19); Pregnancy; Urinalysis; Other (TSH, Allergy, Autoimmune, etc.)]

Pregnancy/Fertility Tests

• Table 5-4: POC Pregnancy and Fertility Test Market Distribution, by End User, 2025 (%) [OTC, PRO]
• Table 5-5: Pregnancy/Fertility POC Test Sales Distribution, by Global Region, 2025 (%) [Europe; Japan; United States; Rest of World]

Colon Cancer Screening

• Table 5-6: Selected POC Colon Cancer Tests
• Table 5-7: Colon Cancer POC Test Sales Distribution, by Global Region, 2025 (%) [Europe; Japan; United States; Rest of World]

Lipid Testing

• Table 5-8: Lipid POC Test Sales Distribution, by Global Region, 2025 (%) [Europe; Japan; United States; Rest of World]

Drugs of Abuse Testing

• Table 5-9: POC Drugs of Abuse Test Sales Distribution, by Setting, 2025 (%) [Criminal Justice; Critical Care – Traditional POC; Employment Screening]

Products

• Table 5-10: Drugs of Abuse Tests on the Market
• Table 5-11: Drugs of Abuse POC Test Sales Distribution, by Global Region, 2025 (%) [Europe; Japan; United States; Rest of World]

Rapid and POC Infectious Disease Testing

• Table 5-12: Innovations in Molecular POC Infectious Disease Diagnostics

Products

• Table 5-13: POC Infectious Disease Test Summary by Disease and Technology

HIV and Hepatitis Testing and Monitoring

Tuberculosis

Tropical and Neglected Diseases

Respiratory Diseases

Sepsis and Nosocomial Disease

Sexual Health

Lyme Disease

COVID-19

Market Size and Growth

Point-of-Care OTC and Professional Use Immunoassays

• Table 5-14: Global POC Immunoassay Sales Distribution, by Region, 2025 (%) [Europe; Japan; United States; Rest of World]
• Table 5-15: Global POC Immunoassay Test Sales, by Test Category, 2025-2030 ($ million) [OTC/Self Tests (Drugs of Abuse; H. pylori; HIV; Infectious Disease/COVID-19; Pregnancy/Ovulation; Other) and Professional POC (Cardiac Markers; Drugs of Abuse; HbA1c; Infectious Disease/COVID-19; Pregnancy; Other)]
• Table 5-16: Selected Self-Test Immunoassay Innovations

Pregnancy Testing

Cardiovascular Diagnostics

Drugs of Abuse/Therapeutic Drug Monitoring

• Table 5-17: Infectious Disease POC Test Demand, by Type, 2025 (%) [C. difficile; COVID-19; E. coli; H. pylori; Hepatitis; HIV; Home Test/OTC; Influenza; Malaria; Other respiratory; STD; Others]
• Table 5-18: Infectious Disease POC Test Sales Distribution, by Global Region, 2025 (%) [Europe; Japan; United States; Rest of World]

Diabetes Testing – Blood Glucose Monitoring

• Table 5-19: Glucose POC Test Sales Distribution, by Global Region, 2025 (%) [Europe; Japan; United States; Rest of World]
• Figure 5-1: POC Glucose Testing Market Growth, by Category, 2025-2030 (%) [Continuous; HbA1c POC, Professional; OTC; Professional]

IT to Aid Diabetes Management

• Table 5-20: Selected Apps and Glucose Management IT

Diabetes Market Analysis

• Table 5-21: Global Diabetes Sales, by Test Category, 2025-2030 ($ million) [Glucose OTC; Glucose, continuous; HbA1c Lab; HbA1c POC]

POC Glucose Competitors

• Table 5-22: Top Three POC Test Vendors, by Glucose Test Revenues, 2025 ($ million)

Blood Glucose Self-Testing

• Table 5-23: Selected Glucose Self-Test Meter Innovations

Non-invasive Testing Devices

• Table 5-24: Selected Noninvasive Glucose Monitoring Devices

Continuous Glucose Monitoring

• Table 5-25: Selected Continuous Blood Glucose System Developments

Blood Glucose Testing by Professionals

• Table 5-26: Selected Innovations in Hospital-based Glucose Monitoring

Diabetes Testing – Glycated Hemoglobin

• Table 5-27: Global HbA1c Test Sales Market and Distribution, by Setting, 2025-2030 ($ million) [HbA1c Lab; HbA1c POC]
• Table 5-28: Selected POC HbA1c Devices

Genes and Other Markers of Diabetes

• Table 5-29: Selected POC Diabetes Monitoring Tests

The Major POC Test Players

• Table 5-30: POC Test Revenues of Selected IVD Companies, 2025 ($ million)

 

Chapter 6: The Core Lab

Scope

Core Lab Overview and Trends

• Table 6-1: Selected Analytes for the Core Lab

Connectivity

Overview of Chemistry Tests

Lab Automation

Market Analysis

• Table 6-2: Global Lab-based Clinical Chemistry Sales, by Test Category, 2025-2030 ($ million) [Blood Gases; General Chemistries; Urinalysis]
• Table 6-3: Global Clinical Chemistry Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]
• Table 6-4: Selected Major Clinical Chemistry Companies, by Sales, 2025 ($ million, estimated)
• Table 6-5: Selected Clinical Chemistry Innovations

Rapid Response Systems

• Table 6-6: Selected Major Whole Blood Chemistry Analyzers

Critical Care Analysis

• Table 6-7: Blood Gas, Electrolyte, and Critical Care Instrument Market, by End User, 2025 and 2030 ($ million) [Lab-based; POC-based]
• Table 6-8: Blood Gas, Electrolyte, and Critical Care Market Leaders, 2025 (% distribution of total sales, including POC)

Urinalysis

• Table 6-9: Urinalysis Market, by End User, 2025 and 2030 ($ million) [Lab-based, POC-based]
• Table 6-10: Urinalysis Systems (including POC) Market Leaders, 2025 (% distribution of total sales, estimated)
• Table 6-11: Selected Urinalysis Innovations

The Commercial Outlook for Chemistry Tests

 

Chapter 7: Immunoassays

Scope

Overview and Trends

Immunoassay Technology Continues to Evolve

• Table 7-1: Selected Immunoassay Technologies

Mass Spectrometry

• Table 7-2: Selected Innovation in Mass Spectrometry for Routine Analyses

Radioimmunoassays

Market Analysis

• Table 7-3: Global Lab-based Immunoassay Sales (excluding infectious disease and blood screening), by Analyte Type, 2025-2030 ($ million)   [Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Drug of Abuse; Fertility; Proteins; Therapeutic Drugs; Thyroid; Tumor Markers; Vitamin D; Others]
• Table 7-4: Global Immunoassay (excluding infectious disease and blood screening) Sales Distribution, by Region, 2025 (%)   [Asia Pacific, Europe, Japan, North America, Rest of World]
• Table 7-5: IVD Quality Control (immunoassay/molecular) Market, 2025 ($ million, estimated)
• Table 7-6: Selected Immunoassay Quality Control Products
• Table 7-7: Revenues of Leading Lab-based Immunoassay Vendors, 2024-2025 ($ million)

Mature Assay Segment

Thyroid Function

Therapeutic Drug Monitoring

Vitamin D

• Table 7-8: Selected Vitamin D Immunoassays

Anemia

Toxicology/DAU

Allergy

Growth Immunoassays

Proteins

• Figure 7-1: Other Proteins, by Percent of Total, 2025 (%)

Tumor Markers

• Table 7-9: Selected Tumor Marker Innovations

Cardiac Markers

• Table 7-10: Regional Cardiac Marker Immunoassay Market Share, by Country, 2025 (%) [EU Countries; Japan; Latin America; Middle East; North America; Rest of Asia Pacific; Rest of Europe; Rest of World]
• Table 7-11: Selected Cardiac Marker Innovations

Autoimmune

• Table 7-12: Selected Autoimmune Test Innovations

Rheumatoid Arthritis

• Table 7-13: Selected Arthritis Immunoassay Innovations

Gastrointestinal Disorders

• Table 7-14: Selected Inflammatory Bowel Disease Test Innovations

Transplant Management

• Table 7-15: Selected Immunoassays for Transplant Medicine

Women’s Health

• Table 7-16: Selected Women’s Health Innovations

Alzheimer’s Disease and Multiple Sclerosis

• Table 7-17: Selected Innovations for Alzheimer’s Disease Immunoassays

Traumatic Brain Injury

Other Immunoassays

• Figure 7-2: Other Select Immunoassays, by Percent of Total Immunoassays, 2025 (%) [Bone Marker; Endocrine/Adrenal; Radioimmunoassays; Others]
• Table 7-18: Selected Immunoassay Innovations

Innovating POC

• Table 7-19: Selected POC Test Innovations
• Table 7-20: Selected POC Immunoassay Test Platforms

The Commercial Outlook for Immunoassays

 

Chapter 8: Molecular Assays

Scope

Overview

• Table 8-1: Common Next Generation Molecular Test Traits

Sample Preparation and Quality Control

• Table 8-2: Selected Molecular Test Sample Preparation and QC Innovations

Molecular Evolution

Exosome Sequencing

• Table 8-3: Selected Exosome Test Innovations

Liquid Biopsy

• Table 8-4: Selected Liquid Biopsy Innovations

Metabolomic Profiling

Information Technology

• Table 8-5: Selected IT Innovations in Molecular Diagnostics

Artificial Intelligence (AI)

Forensic Studies – An Emerging Opportunity

• Table 8-6: Selected Innovations in Forensic DNA Testing

Test Platforms

• Table 8-7: Key Molecular Technologies and Major Players
• Table 8-8: Selected Molecular Test Platform Innovations

Major Players

• Table 8-9: Molecular Test Revenues of Selected IVD Vendors, 2022, 2023, 2024, and estimated 2025 ($ million)

Market Analysis

• Table 8-10: Global Genomic, HLA, NIPT, and Oncology Molecular Test Sales, by Type with NIPT, 2025-2030 ($ million)

Oncology

• Table 8-11: Global Molecular Cancer Test Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]
• Table 8-12: Selected Molecular Tumor Marker Test Innovations

Inherited/Genetic Diseases, Thrombophilia SNPs and Other Disorders

• Table 8-13: Most Frequently Requested Genetic Tests
• Table 8-14: Global Molecular Thrombophilia Assay Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

Alzheimer’s Disease and Dementia

Cardiovascular Disease

• Table 8-15: Selected Genomic Tests for Inherited Diseases

Depression and Psychiatric Disorders

Prenatal and Newborn Testing

• Table 8-16: Global Prenatal Test Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]
• Table 8-17: Selected Prenatal Services Provided
• Table 8-18: Selected Molecular Tests for Prenatal Analysis

Transplant Diagnostics

• Table 8-19: Global Molecular HLA Testing Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]
• Figure 8-1: Global Transplant Rate, by Region, 2024
• Table 8-20: Selected Innovations of Molecular Transplant Diagnostics

Women’s Health

The Commercial Outlook for Molecular Tests

 

Chapter 9: Hematology

Scope

Overview of Hematology and Trends

• Table 9-1: Hematology Analyzer Distribution of Sales, by Menu Capability, 2025 estimated (%)
• Table 9-2: Lab-based Hematology Sales, by Analyte Average Annual Distribution, 2025 (%)

Digital Image Analysis

• Table 9-3: Selected Hematology Image Analysis Innovations

Digital Evolution

Quality Control Measurement Programs

• Table 9-4: Selected Quality Control Hematology FDA Registrations, 2024

Laboratory-based Hematology Testing

• Table 9-5: Selected Hematology Innovations
• Table 9-6: Global Laboratory-based Hematology Test and Instrument Market, 2025 and 2030 ($ million)

Regional Laboratory-based Hematology Test and Instrument Market

• Table 9-7: Global Laboratory-based Hematology Test and Instrument Market, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

Decentralized Hematology Testing

Hemoglobin/Hematocrit at the POC

• Table 9-8: POC Hematology Distribution, by Specialty, 2025 (%) [Hematocrit/Hemoglobin vs. Other Routine Hematology (WBC, Erythrocyte, Platelet)]
• Table 9-9: Selected POC Hemoglobin and Hematocrit Systems
• Table 9-10: Selected POC Hematology Analyzer Systems
• Table 9-11: Decentralized Hematology Test and Instrument Market, by Type, 2025 and 2030 ($ million) [Instruments, Lab-Style; Handheld Devices]

Market Analysis: Leading Suppliers

• Table 9-12: Top Hematology Company Revenues (Laboratory and POC), 2025 ($ million)
• Figure 9-1: Market Share for Top Hematology Companies (Laboratory and POC), 2025 (%)
• Table 9-13: Global Hematology (Laboratory-based and POC) Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

The Commercial Outlook for Hematology Tests

 

Chapter 10: Coagulation

Scope

Overview and Trends of Coagulation and Immunohematology Tests

COVID-19

Direct Oral Anticoagulants (DOACs)

D-dimer

• Table 10-1: Global D-dimer Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

Market Analysis

• Table 10-2: Global Coagulation Sales, by Segment, 2025-2030 ($ million) [D-dimer; Molecular; Professional POC; Professional Self; PT/INR Labs]
• Table 10-3: Global Coagulation Test and Instrument Market, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

Lab-based Testing

• Table 10-4: Selected Lab-based Coagulation Innovations

Genetic Markers of Hypercoagulopathies

• Table 10-5: Related CMS Codes for Reimbursement National Limits, Molecular, 2025
• Table 10-6: Global Molecular – Thrombophilia SNP Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]
• Table 10-7: Selected Molecular Coagulation Test Innovations

Leading Suppliers: Laboratory Systems

• Table 10-8: Top Coagulation Company Market Share Laboratory-based, 2025 (%)

Decentralized Coagulation Testing – Professional Use

Decentralized Coagulation Testing – OTC

• Table 10-9: Selected POC Coagulation Test Innovations

Platelet Testing

• Table 10-10: Selected Platelet Activity Test Innovations

Leading Suppliers: POC Systems

• Table 10-11: Top Coagulation Company Revenues, POC, 2025 ($ million, estimated)

The Commercial Market for Coagulation Tests

• Table 10-12: Major Anticoagulants Uses and Tests

 

Chapter 11: Microbiology and Virology

Scope

The Real Impact of Infections

Herpes and Alzheimer’s Disease

Ebola and Cancer

HIV and Cancer

H pylori and Cancer

Bacteria and Parkinson’s

HPV and Cancer

Microbial Antibiotic Resistance – The Role of Clinical Tests

Fast Identification

• Table 11-1: Selected Companies Developing Faster Identification, Some Also with Antimicrobial Susceptibility/Resistance Tests

Traditional Microbiology and Its Limits

The New Microbiology – Innovations

Liquid Based Microbiology and Automation Innovations

Post-Blood Culture Microbial ID

PCR and Other NAAT-Based Tests for Infectious Diseases

• Table 11-2: Selected Nucleic Acid Amplification Test and Other Molecular Companies in Microbiology

Microbiome-Related Microbiology Tests

Illumina

Bio-Rad

QIAGEN

Luminex (Diasorin)

inBiome BV

DNA Genotek

Thermo Fisher Scientific

Others

Next-Generation Sequencing-Based Microbiology Approaches

• Table 11-3: Selected Companies Applying DNA/RNA Sequencing to Microbiology

Syndromic/Multiplex Testing

High-Consequence Infectious Disease Threats

• Table 11-4: Selected Companies Marketing Products Addressing High-Consequence Infectious Disease Threats

Tickborne Diseases (TBDs)

TB and Other Infectious Diseases

Chagas

Dengue

Ebola

Chikungunya

Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)

Marburg

SARS-CoV-2 (COVID-19)

Monkeypox

Market Analysis

• Table 11-5: Global Microbiology Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

Market Analysis – Traditional Microbiology ID/AST

• Table 11-6: Global Microbiology ID/AST Market, by Segment, 2025-2030 ($ million) [Blood Culture; Chromogenic Media; ID/AST Auto; ID/AST Panels; Rapid Microbiology]
• Table 11-7: Global ID/AST Testing Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

Traditional ID/AST

• Table 11-8: Global ID/AST Testing, Distribution by Systems, (%) [Auto, Panel]

Blood Culture

• Table 11-9: Selected Advanced Techniques in Positive Blood Culture

Chromogenic Media

Rapid Tests Performed on Colonies from Culture Media

Supplies

Market Analysis – Microbiology Immunoassays

Improvements in Microbiology Immunoassays

• Figure 11-1: Immunoassay Respiratory Testing, by Target Pathogens, 2025 (%) [Multi-Target, Single-Target]
• Table 11-10: Selected Infectious Disease Immunoassay Innovations
• Table 11-11: Global Clinical Laboratory-Based Microbiology/Infectious Disease Immunoassay Market, by Pathogen, 2025($ million)   [HAIs/Sepsis; Hepatitis; HIV; Lyme Disease; Mycology; Parasitology; Respiratory; STDs; ToRCH; Other]
• Table 11-12: Global Laboratory-Based Microbiology/Infectious Disease Immunoassay Market Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

Hepatitis Testing

Sepsis

• Figure 11-2: Global Lab-based Microbiology Immunoassay Sepsis Market Distribution, by Type, 2025 (%) [PCT, Traditional]

HIV Immunoassay Testing

• Table 11-13: Selected HIV Assays

Sexually Transmitted Diseases (STDs)

ToRCH

Lyme Disease

Market Analysis – Molecular Microbiology

• Table 11-14: Global Molecular Microbiology Sales Distribution by Region, 2025 (%) [Asia Pacific, Europe, North America, RoW]
• Table 11-15: Global Molecular Microbiology Market, by Pathogen/Disease Indication, 2025-2030 ($ million) [Blood Bank Screening; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Organism ID; Respiratory; Others]

Lab Automation and Molecular Diagnostics

• Table 11-16: Selected Automated Molecular Test Instrument Platforms

Molecular Respiratory Infection Testing

The Respiratory Trio – Flu, Strep, RSV

• Figure 11-3: Molecular Respiratory Testing, by Target Pathogens, 2025 (%) [Multi-Target, Single-Target]

Molecular Testing for Sexually Transmitted Diseases

Molecular Hepatitis Testing

Molecular HIV Testing

• Table 11-17: Innovations in Molecular POC Diagnostics for HIV

Molecular Tests for Hospital-Acquired Infections (HAIs)

• Table 11-18: Frequency of the Most Common Nosocomial Infections

Assessing the Problem: Nosocomial Infection Statistics

Clostridium Difficile

MRSA

Molecular TB Testing

Limitations of Molecular Microbiology Testing

Rapid Microbiology Tests

• Table 11-19: Global Rapid Microbiology Testing Market, Sales Distribution, by Pathogen, 2025 (%) [C. Difficile; COVID-19; E. coli; H. pylori; Hepatitis; HIV; Influenza; Malaria; Other respiratory; STD; Other]
• Figure 11-4: Rapid Infectious Disease Test Sales, by Respiratory/Non-respiratory Segments, 2025 (%)
• Figure 11-5: Rapid Respiratory Testing, by Target Pathogens, 2025 (%) [Multi-Target, Single-Test]

Mass Spectrometry

• Table 11-20: Selected Companies Marketing Mass Spectrometers and/or Assays for the Clinical Laboratory [CE-Marked and/or 510(k) cleared]

The Future Outlook for Microbiology

 

Chapter 12: Blood Banking Services

Scope

Overview

The Current Status of Global Blood Collection

Global Blood Safety

• Table 12-1: Laboratory Screening of Blood Donations for Transfusion-Transmissible Infections, Number of Countries [Chagas; HBV; HCV; HIV; HTLV I/II1; Malaria; Syphilis]
• Table 12-2: Prevalence of TTIs in Blood Donations [Median (Interquartile range)], by Income Group

Zika Virus

Blood and Component Collection

• Table 12-3: Blood Component Usage for Selected Conditions

Reevaluating Blood Transfusions

• Table 12-4: Impact of Alloimmunization (% of Patients Screening Positive for One or More Antibodies)

Blood Typing and Grouping Market

Manual Blood Typing Methods

Automated Blood Typing and Screening Methods

Molecular Methods

• Table 12-5: Selected Blood Typing and Grouping Innovations

Size and Growth of Typing Markets

• Table 12-6: Global Blood Typing Market, 2025-2030 ($ million)

Blood Typing Market by Geography

• Table 12-7: Global Blood Typing Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

Blood Testing Market

• Table 12-8: Selected Blood Testing Innovations

Preventing Bacterial Infections

Immunoassays

Nucleic Acid Testing (NAT)

Size and Growth of the Market

• Table 12-9: Global Blood Banking Diagnostics Market, 2025-2030 ($ million) [Immunoassay Screen; NAT Screens]

Blood Testing Market by Geography

• Table 12-10: Global Blood Testing Market, by Geography, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]

The Commercial Outlook for Blood Banking Testing

 

Chapter 13: Histology and Cytology

Scope

Overview

Special Topics

Histology Automation

• Table 13-1: Selected Histology Lab Automation
• Table 13-2: Histology Information Technology Tools

Advanced Analysis Solutions

• Table 13-3: Selected Advanced Histology Techniques

HPV IVD Testing Becomes Main Stream

• Table 13-4: Global HPV Test Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]
• Table 13-5: Selected HPV Test Innovations

Market Analysis

Total Market

• Table 13-6: Global Histology/Cytology Sales, by Type, 2025-2030 ($ million) [HPV; Immunohistochemistry; in situ hybridization; Pap Tests; traditional non-Pap stains]

Regional Market Analysis

• Table 13-7: Global Histology/Cytology Sales Distribution, by Region, 2025 (%) [Asia Pacific; Europe; North America; Rest of World]
• Table 13-8: Revenues of the Major Histology Companies, 2018-2025 ($ million, estimated)

Traditional Stains

• Table 13-9: Selected Vendors of Traditional Histology Stains

Pap Testing

• Table 13-10: Primary and Secondary Prevention of Cervical Cancer, Screening Responses, by Country, 2021
• Table 13-11: Three approaches to cervical cancer screening and future tests

Immunohistochemistry and In Situ Hybridization

• Table 13-12: Selected In Situ Hybridization-based Tests
• Table 13-13: Selected IHC Test Innovations

Pharmacodiagnostic Histology

• Table 13-14: Major Pharmacodiagnostic Markers
• Table 13-15: Selected Pharmacodiagnostic Histology Tests

Digital Imaging and Computational Pathology

• Table 13-16: Selected Digital Pathology Image Capture and Viewing Solutions
• Table 13-17: Selected Digital Imaging Innovations

Circulating Tumor Cells

• Table 13-18: Innovations in CTC Technology

Flow Cytometry

The Commercial Outlook for Histology and Cytology Tests

 

Chapter 14: Company Profiles: The Top Tier

Scope

Abbott Diagnostics

• Table 14-1: Abbott Diagnostics Revenue History, 2023-2025 ($ million)
• Table 14-2: Abbott Diagnostic Revenues, by Segment, 2023-2025 ($ million, estimated)

Core Lab

Hematology

Blood Banking

Infectious Diseases – Molecular

Diabetes

HIV Point of Care

i-STAT Business

Agilent Technologies

• Table 14-3: Agilent Revenue History, 2023-2025 ($ million)

Genomics

Cytogenetic Analysis

Sequencing

CRISPR

Flow Cytometry

Companion Diagnostics – Dako

Digital Pathology

Beckman Coulter / Danaher

Hematology

Hematology IT

Clinical Chemistry

Immunoassays

Microbiology

IT Clinical

Flow Cytometry

Blood Banking

Beckman Coulter Life Sciences

Becton, Dickinson and Company (BD)

• Table 14-4: BD Revenue History, 2023-2025 ($ million, estimated) FYE Sept 30

Cytology

Molecular Microbiology

Traditional Microbiology – ID/AST

Blood Culture

Hospital Acquired Infections

Blood Collection

Mass Spectrometry

Flow Cytometry

Immunoassay

bioMérieux Inc.

• Table 14-5: bioMérieux Revenue History, 2023-2025 (€ million)

Traditional Microbiology

Blood Culture

Immunoassays

Mass Spectrometry

BIOFIRE Diagnostics Business

Expansion

Bio-Rad Laboratories, Inc.

• Table 14-6: Bio-Rad Revenue History, 2023-2025 ($ million, estimated)

Quality Control

Blood Bank

Diabetes

Immunoassays

Liquid Biopsy

Droplet Digital PCR

Sequencing

Bruker Corporation

• Table 14-7: Bruker Revenue History Product Revenue, 2023-2025 ($ million)

Acquisitions and Collaborations

Mass Spectrometry

Microbiology

Molecular PCR

Cepheid / Danaher

GeneXpert/ Xpress Line

Tuberculosis

Microbiology

POC Testing

Cancer

Danaher Corporation

• Table 14-8: Danaher Revenue History, Diagnostics Segment, 2023-2025 ($ million, estimated)

Dexcom

• Table 14-9: Dexcom Revenue History, 2023-2025 ($ million)

Exact Sciences

• Table 14-10: Exact Sciences Revenue History, 2023-2025 ($ million)

Hologic, Inc.

• Table 14-11: Hologic Revenue History, Diagnostic Product Revenue, 2023-2025 ($ million)

PANTHER Molecular System

Sexually Transmitted Infections

Infectious Diseases

PANTHER Fusion

Cytology

Illumina

• Table 14-12: Illumina Revenue History, 2023-2025 ($ million, not all revenues are for clinical products and services; estimated)

China

Leica Biosystems/Danaher

Digital Pathology

Tissue Staining

Lab Systems

Natera

• Table 14-13: Natera Revenue History, 2023-2025 ($ million)

QIAGEN

• Table 14-14: QIAGEN Revenue History, 2023-2025 ($ million)

Tuberculosis.

Molecular Expansion

Precision Medicine / Companion Diagnostics

Molecular Microbiology

Prenatal Testing

Next-Generation Sequencing

Liquid Biopsy

Cervical Cancer

Expansion

QuidelOrtho Corporation

• Table 14-15: QuidelOrtho Revenue History, 2023-2025 ($ million)
• Table 14-16: QuidelOrtho Diagnostic Revenues, by Segment, 2023-2025 ($ million, estimated)

Immunoassays

Rapid Immunoassays

The Solana Business

Blood Bank

Radiometer A/S / Danaher

Critical Care

Immunoassays

HemoCue

Transcutaneous Monitoring

Revvity

• Table 14-17: Revvity Revenue History, 2023-2025 ($ million, estimated)

Roche Diagnostics

• Table 14-18: Roche Revenue History, 2023-2025 (CHF million)
• Table 14-19: Roche Diagnostic Revenues, by Segment, 2023-2025 (CHF million)

Hematology

Immunoassays

HIV

Molecular Expansion

Core Molecular

Digital PCR

Diabetes Care

Coagulation

cobas Liat System – POC

HPV

Blood Bank

Transplant Medicine

Sequencing and Mass Spectrometry

Cancer Companion Testing

Information Technology

Roche Tissue Diagnostics

Immunohistochemistry – IHC

Cervical Cancer Screening

Companion Diagnostics

Siemens Healthineers (Siemens)

• Table 14-20: Siemens Healthineers Revenue History, 2023-2025 (€ million)

Core Lab

Lab Automation

Immunoassays

Hematology

Urinalysis

Molecular

Sequencing with Artificial Intelligence

Acute Care – POC

POC Connectivity

Business Expansion

Sysmex Corporation

• Table 14-21: Sysmex Revenue History, 2023-2025 (billions of Yen) FYE March 31

Hematology

Coagulation

Urinalysis

Immunoassays

Lab Information System

Flow Cytometry

Precision Medicine / Companion Test Diagnostics

Liquid Biopsy

Sysmex Inostics

Forging New Markets

Thermo Fisher Scientific Inc.

• Table 14-22: Thermo Fisher Revenue History, Clinical Diagnostics, 2023-2025 ($ million)

Immunoassays

Microbiology

Molecular Test Business

Next-Generation Sequencing

qPCR

Oncology Companion Diagnostics

Transplant Medicine

Mass Spectrometry

Werfen

• Table 14-23: Werfen Recent Revenue History, 2023-2025 (€ billion)

 

Chapter 15: Company Profiles: The Second Tier

Scope

ARKRAY

Dry Chemistry / Immunoassays

Urinalysis

BGI Genomics (formerly Beijing Genome Institute)

MGI Tech Co., Limited, China

Prenatal Testing

Test Services

Whole Genome Sequencing (WGS)

NGS Sequencing

Biocartis

Diagnostica Stago S.A.S.

Diasorin S.p.A

POC

Immunoassays

Molecular

Molecular Oncology

Eiken Chemical Co., Ltd

Fujirebio Diagnostics, Inc.

Fulgent Genetics, Inc

GeneDx

Grifols S.A.

Blood Transfusion Business

ABO Blood Typing

Molecular ABO Blood Typing

Immunoassays

Guardant Health, Inc.

Haemonetics

Horiba

Menarini Diagnostics

Meridian Bioscience, Inc.

Mindray – Shenzhen Mindray Bio-medical Electronics Co., Ltd.

Myriad Genetics, Inc.

OraSure Technologies, Inc.

Randox Laboratories Ltd.

Clinical Chemistries

POC and Rapid

Companion Diagnostics

Controls

Evidence Series – Multistat Biochip Analyzers

Molecular

Seegene, Inc.

Sekisui Diagnostics LLC

Veracyte, Inc.

 

Chapter 16: Company Profiles: Blood Bank Specialists

Scope

AliveDx

Cerus Corporation

 

Chapter 17: Company Profiles: Core Lab and Other Companies

Scope

SCIEX Pte Ltd.

Diabetes

Molecular

EKF Diagnostics Holdings Plc

Shimadzu Scientific Instruments

Snibe Co. Ltd. (Shenzhen New Industries Biomedical Engineering Co. Ltd.)

Tosoh Bioscience

Trinity Biotech Plc

 

Chapter 18: Company Profiles: CTC & Liquid Biopsy Test Providers

Scope

Epic Sciences

Foundation Medicine, Inc.

NeoGenomics

 

Chapter 19: Company Profiles: Specialists

Scope

Ascensia Diabetes Care Holdings AG

Insulet Corporation

Medtronic plc

Verily Life Sciences LLC

 

Chapter 20: Company Profiles: Hematology (Cell Analysis) and Coagulation Specialists

Scope

CellaVision AB

Masimo Corporation

Nova Biomedical Corporation (Nova)

 

Chapter 21: Company Profiles: Histopathology Specialists

Scope

Amoy Diagnostics Co. Ltd.

Applied Spectral Imaging Inc. (ASI)

Visiopharm

 

Chapter 22: Company Profiles: Immunoassay Specialists

Scope

Biohit Healthcare

Biomerica Inc.

Bio-Techne Corporation

Eurobio Scientific

EUROIMMUN AG (Revvity)

INOVA Diagnostics, Inc.

VolitionRx Limited

 

Chapter 23: Company Profiles: Microbiology Specialists

Scope

Advanced Biological Laboratories, S.A. (ABL)

altona Diagnostics

ArcDia International Oy Ltd.

COPAN ITALIA S.p.A. and COPAN Diagnostics, Inc.

Genetic Analysis AS

Q-linea AB

 

Chapter 24: Company Profiles: Molecular Test Specialists

Scope

Pacific Biosciences of California, Inc. (PacBio)

Standard BioTools

 

Chapter 25: Company Profiles: Point of Care Test Specialists

Scope

Abingdon Health Ltd.

binx Health

Chembio Diagnostic Systems, Inc.

Genedrive plc (formerly Epistem Holdings)

MedMira, Inc.

 

Chapter 26: Company Profiles: Prenatal Test Service Providers

Scope

Berry Genomics Co. ltd.

INEX Innovate

Oxford Gene Technology

Yourgene Health

 

Chapter 27: Company Profiles: Quality Control & Sample Pretreatment Specialists

Scope

Agena Bioscience, Inc.

Biotype Diagnostic GmbH

IncellDx

LGC SeraCare Life Sciences, Inc.

PreAnalytiX GmbH

Precipio, Inc.

Quanterix Corporation

Streck Inc.

 

Chapter 28: Test Service Providers

Scope

Agendia BV

Ambry Genetics

ARUP Laboratories

Aspira Women’s Health

Blueprint Genetics Oy

Boston Heart Diagnostics

CareDx, Inc.

Predictive Oncology

Labcorp, Laboratory Corporation of America

Mayo Clinic Laboratories

MDxHealth SA

OPKO Diagnostics/Opko Health

Quest Diagnostics

Sonic Healthcare